IGHG3 and B-cell non-Hodgkin lymphoma: These results are consistent with our previous in vitro studies demonstrating that RTX-IgG3 has the greatest potential of RTX isotypes to induce ADP, as well as complement-dependent cytotoxicity, in 2D and 3D-cultured CD20+ B-cell lymphoma [6, 23].